Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
There is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Interdisciplinary Perspectives on Infectious Diseases |
Online Access: | http://dx.doi.org/10.1155/2011/830286 |
id |
doaj-743a297193ae41139cd80a590b640fe8 |
---|---|
record_format |
Article |
spelling |
doaj-743a297193ae41139cd80a590b640fe82020-11-24T22:16:24ZengHindawi LimitedInterdisciplinary Perspectives on Infectious Diseases1687-708X1687-70982011-01-01201110.1155/2011/830286830286Cryptococcus neoformans as a Model for Radioimmunotherapy of InfectionsEkaterina Dadachova0Arturo Casadevall1Department of Nuclear Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USADepartment of Microbiology and Immunology, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USAThere is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment, has been successfully adapted for the treatment of experimental fungal, bacterial, and viral infections. As our model organism for studying the efficacy, mechanisms, potential toxicity, and radioresistance to RIT, as well as for comparison of RIT with the existing antimicrobial therapies we have chosen the encapsulated yeast Cryptococcus neoformans (CN). The success of RIT approach in laboratory studies provides encouragement for feasibility of therapeutically targeting microbes with labeled antibodies. In addition, the creation of “panantibodies” for RIT which would recognize antigens shared by the whole class of pathogens such as fungi, for example, would facilitate the introduction of RIT into the clinic.http://dx.doi.org/10.1155/2011/830286 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ekaterina Dadachova Arturo Casadevall |
spellingShingle |
Ekaterina Dadachova Arturo Casadevall Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections Interdisciplinary Perspectives on Infectious Diseases |
author_facet |
Ekaterina Dadachova Arturo Casadevall |
author_sort |
Ekaterina Dadachova |
title |
Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections |
title_short |
Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections |
title_full |
Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections |
title_fullStr |
Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections |
title_full_unstemmed |
Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections |
title_sort |
cryptococcus neoformans as a model for radioimmunotherapy of infections |
publisher |
Hindawi Limited |
series |
Interdisciplinary Perspectives on Infectious Diseases |
issn |
1687-708X 1687-7098 |
publishDate |
2011-01-01 |
description |
There is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment, has been successfully adapted for the treatment of experimental fungal, bacterial, and viral infections. As our model organism for studying the efficacy, mechanisms, potential toxicity, and radioresistance to RIT, as well as for comparison of RIT with the existing antimicrobial therapies we have chosen the encapsulated yeast Cryptococcus neoformans (CN). The success of RIT approach in laboratory studies provides encouragement for feasibility of therapeutically targeting microbes with labeled antibodies. In addition, the creation of “panantibodies” for RIT which would recognize antigens shared by the whole class of pathogens such as fungi, for example, would facilitate the introduction of RIT into the clinic. |
url |
http://dx.doi.org/10.1155/2011/830286 |
work_keys_str_mv |
AT ekaterinadadachova cryptococcusneoformansasamodelforradioimmunotherapyofinfections AT arturocasadevall cryptococcusneoformansasamodelforradioimmunotherapyofinfections |
_version_ |
1725790113798029312 |